Moexipril-d5 intended for use as an internal standard for the quantification of moexipril by GC- or LC-MS. Moexipril is a prodrug form of the angiotensin converting enzyme (ACE) inhibitor moexiprilat.1 It is converted to moexiprilat in vivo by side chain ester hydrolysis.2 Moexipril inhibits ACE in a cell-free assay (IC50 = 2.7 µM for the rabbit enzyme). It also inhibits phosphodiesterase 4 (IC50s = 38, 160, and 230 µM for PDE4B2, PDE4A5 and PDE4D5, respectively).2 Moexipril (0.1-30 mg/kg per day) reduces blood pressure in spontaneously hypertensive rats.1 It also reduces infarct volume in a rat model of focal cerebral ischemia when used at a concentration of 0.01 mg/kg.3
1.Edling, O., Bao, G., Feelisch, M., et al.Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: Pharmacological characterization and comparison with enalaprilJ. Pharmacol. Exp. Ther.275(2)854-863(1995) 2.Cameron, R.T., Coleman, R.G., Day, J.P., et al.Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4)Biochem. Pharmacol.85(9)1297-1305(2013) 3.Ravati, A., Junker, V., Kouklei, M., et al.Enalapril and moexipril protect from free radical-induced neuronal damage in vitro and reduce ischemic brain injury in mice and ratsEur. J. Pharmacol.373(1)21-33(1999)